Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records

Kitamura, Noboru; Takahashi, Yasuo; Yamadate, Shuukoh; Asai, Satoshi
January 2007
Cardiovascular Diabetology;2007, Vol. 6, p26
Academic Journal
Background: A beneficial effect on glucose metabolism is reported with angiotensin receptor blocker (ARB) treatment of hypertension. The effect on blood glucose level during the course of treatment with ARBs in clinical cases is uncertain. Our objectives were to survey the changes in glucose and HbA1c levels in patients with hypertension over a one-year period, and to study the correlations between these values and the time after the start of ARB therapy. Methods: We conducted a retrospective longitudinal survey of blood glucose and HbA1c measurements in Japanese patients aged &≥20 years with newly diagnosed hypertension but without diabetes, who had received ARB monotherapy with candesartan cilexetil, losartan potassium, olmesartan medoxomil, telmisartan, or valsartan during the period from December 2004 to November 2005. Data including 2465 measurements of non-fasting blood glucose in 485 patients and 457 measurements of HbA1c in 155 patients were obtained from electronic medical records of Nihon University School of Medicine. Linear mixed effects models were used to analyze the relationship between these longitudinal data of blood examinations and covariates of patient age, sex, medication, and duration of ARB therapy. Results: Casual blood glucose level was associated with the duration of treatment (P < 0.0001), but not with age, sex, or medication. Blood glucose level was significantly decreased during the periods of 0∼3 months (P < 0.0001) and 3∼6 months (P = 0.0081) compared with baseline, but was not significantly different between 6∼12 months and baseline. There was no association between HbA1c level and covariates of sex, age, medication and duration of treatment. Conclusion: Our findings provide new clinical evidence that the effects of ARBs on glucose metabolism may change during the course of treatment, suggesting a blood glucose-lowering effect in the short-term after the start of treatment.


Related Articles

  • Renin-Guided Treatment of Hypertension: Time for Action. Furberg, Curt D. // American Journal of Hypertension;Sep2010, Vol. 23 Issue 9, p929 

    The author reflects on the treatment of hypertension using Laragh and colleagues study as a guide. According to the author, Laragh and colleagues found out that there are four major types of hypertension including low-renin, medium/high-renin, and resistant hypertension. He says that rennin...

  • ARBs 'do not lower' AF incidence. Moberly, Tom // GP: General Practitioner;4/24/2009, p12 

    The article offers information on the study conducted on the implication of angiotensin II-receptor blockers (ARB) to hypertensive patients in England. Result reveals that ARB do not reduce incidence of recurrent atrial fibrillation (AF). Moreover, the addition of valsartan to therapies for AF...

  • Highlights.  // American Journal of Hypertension;May2011, Vol. 24 Issue 5, p503 

    The article offers information on the research studies related to the therapeutic efficacy of angiotensins in patients with hypertension and early onset-diabetes. A randomized meta-analysis study of renin inhibitor aliskiren and angiotensin receptor blocker (ARB) in blood pressure is presented....

  • Monitoring renal function in hypertension. Martin, Una; Coleman, Jamie J. // BMJ: British Medical Journal (International Edition);10/28/2006, Vol. 333 Issue 7574, p896 

    We present two typical cases seen in a hospital hypertension clinic that illustrate the role of measurement of electrolytes and renal function in patients treated with angiotensin inhibitors (angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists) or potassium...

  • Results From The KYOTO HEART Study.  // MD Conference Express;Nov2009, p11 

    The article highlights results from the Kyoto Heart Study, spearheaded by Professor H. Matsubara of Kyoto Prefectural University of Medicine in Tokyo, Japan. It is stated that the study focuses on the effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high...

  • Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Baumhäkel, M; Schlimmer, N; Böhm, M // International Journal of Impotence Research;Sep/Oct2008, Vol. 20 Issue 5, p493 

    Pathogenesis of erectile dysfunction (ED) is related to endothelial dysfunction and therefore associated with cardiovascular risk factors. Patients with a combination of risk factors, as in metabolic syndrome, are thus likely to have an increased risk of developing endothelial and ED. The...

  • Fixed-Dose Combinations in Hypertension. Narroden, Salomon; Antonios, Tarek F. T. // Current Medical Literature: Cardiology;2009, Vol. 28 Issue 4, p81 

    This article discusses the fixed-dose combination therapy in hypertension. Hypertension is a risk factor for cardiovascular disease mortality and morbidity. A comparison between the fixed-dose combination and the first-line therapies using a single drug is presented, including diuretic plus...

  • Defining the role of renin/angiotensin targeted antihypertensive therapy. Probstfield, Jeffrey // Journal of Family Practice;Jun2009, Vol. 58 Issue 6, pS1 

    The article reports on a study that evaluates the effectiveness of renin-angiotensin-aldosterone system (RAAS) to treat hypertension. It suggests selecting treatment that focuses on achieving blood pressure (BP) goals because the major benefits of antihypertensive treatment results from BP...

  • What we really need to do to reduce cardiovascular events in hypertensive patients.  // Journal of Family Practice;Sep2007, Vol. 56 Issue 9, p727 

    The article discusses the antihypertensive drug trials conducted with the aim of reducing cardiovascular-related diseases in hypertensive patients. The study was participated by 500 patients and were observed for at least three years through the utilization of randomized controlled trials. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics